BUSINESS
Closing Bell: Sensex up 179 points, Nifty above 18,300; IndusInd, PowerGrid, Tata Motors top gainers
Closing Bell: Nifty Realty, Oil & Gas and Auto were the top sectoral gainers
BUSINESS
US sales, brand deals to seal the fortune for Dr Reddy's in Q4
Dr Reddy's is poised to reap the benefits of brand sales of Rs 275 crore, which will incrementally boost its headline numbers for Q4.
BUSINESS
Closing Bell: Indices close flat, Nifty near 18,250; ITC, SBI, Bajaj Finance worst hit
Closing Bell: Nifty IT, Pharma, Auto shine, PSU Banks, Realty worst hit.
BUSINESS
One-time loss, weak operational performance drags UPL Q4 earnings below street expectations
The company also missed the target to reduce its net debt by $500 million during FY22-23. Going ahead, UPL has guided a revenue growth of 6-10 percent and an EBIDTA growth of 8-12 percent.
BUSINESS
UPL shares trade marginally higher on hopes of robust Q4 earnings
According to ShareKhan by BNP Paribas, UPL is likely to defy industry trends during Q4 and exhibit a better performance due to its global market exposure and the advantage of backward integration.
BUSINESS
Closing Bell: Sensex gains 710 pts, Nifty settles above 18,250; Tata Motors, IndusInd Bank, Bajaj Finance shine
Closing Bell: Most sectoral indices settled in the green.
BUSINESS
Chemicals Q4 preview: A mixed bag, agri-input companies seen weak, specialty chemicals firms may grow
Despite the near-term headwinds for the chemicals sector, the street's long-term view remains positive due to the strong prospects for specialty chemicals and a huge import replacement opportunity.
BUSINESS
Here's why it’s time to take note of small and mid-cap pharma stocks
Deriving a higher share of revenue from the domestic market is a major positive for companies such as Ajanta Pharma and JB Chemicals & Pharmaceuticals.
BUSINESS
Closing Bell: Nifty above 18,000, Sensex gains 463 pts; all sectors in the green
BSE Midcap and smallcap indices up 1 percent each.
BUSINESS
Why investors gave a thumbs down to Ipca Labs’ Unichem acquisition?
Analysts believe Ipca Labs would have been better-placed had they committed this growth capital to secularly growing within the India market.
BUSINESS
Lupin shares bounce back 10.5% in one month; should investors jump on the bandwagon?
Opinion is split, but most analysts recommend waiting for more clarity from Lupin.
BUSINESS
Ipca Labs hits fresh 52-week low as Unichem acquisition spoils mood for second day
Unfavourable risk reward, plain-vanilla portfolio and a subdued financial performance are reasons behind the street's disappointment over the Ipca-Unichem acquisition.
BUSINESS
Are pharma cos poised for a bull ride? Here's what analysts believe
Alok Dalal of Jefferies believes the $27 billion domestic pharma industry is well-placed to achieve low double-digit growth in the coming years on increased spending on medicines as the population starts to age.
BUSINESS
Ami Organics shares surge 4% on plans to acquire 55% in Baba Fine Chemicals
Baba Fine Chemicals is involved in the manufacturing of custom specialty chemicals used in semiconductor industry.
BUSINESS
Sun Pharma slips 3% on production halt at Mohali unit for corrective actions
JP Morgan sees a limited 1-2 percent impact on Sun Pharma's FY24 earnings due to the production halt.
BUSINESS
Sun Pharma pauses production at Mohali facility to implement US FDA corrective actions
Sun Pharma said that US shipments from the Mohali facility will resume once these measures are set in place.
BUSINESS
Midcap Magic | Ajanta Pharma favoured by analysts for long-term growth
Specialising in branded generics, Ajanta Pharma operates in over 30 countries. The company has also invested significantly in diversifying its products and regional mix to expand to untapped markets in Africa and the Asia-Pacific
BUSINESS
JP Morgan has downgraded 2 IT players; here is why
The brokerage firm attributed the ratings cut to signs of prolonged weakness in BFSI and telecom verticals for these IT companies
BUSINESS
ICICI Securities plummets 6% as Q4 net tanks 23% on higher cost of funds
ICICI Securities' weak quarterly performance is at a stark contrast to that of industry rival, Angel One, which posted a robust set of Q4 numbers on Monday.
BUSINESS
Hospital sector likely to firm up on higher occupancy, favourable base in Q4
Most brokerages anticipate that the trend of capacity expansion will persist throughout the sector. Investor attention will remain focused on management commentaries for insights into plans to expand capacity, as well as the potential impact of this on profitability and margins.
BUSINESS
MFs sell Dr Reddy’s shares for three consecutive months; stock still gains 16% year-to-date
The reduction in exposure to Dr. Reddy's may have ben to invest in other companies of similar size such as Cipla or Sun Pharma that are expected to deliver better growth and returns, says one fund manager.
BUSINESS
Bernstein starts coverage on Delhivery with 'market-perform' rating, sees 11% upside
Bernstein sees Delivery's medium term revenue growth in mid-teens with an adjusted EBITDA breakeven in FY24.
BUSINESS
Nuvama sees high risk of OAI classification as Lupin facility faces US FDA heat
Domestic pharma companies have been struggling with heightened scrutiny from the US FDA after physical checks resumed post COVID. The FDA's approval is vital for Indian drugmakers as a major chunk of their revenues are made up of sales in the US market.
BUSINESS
Highest risk, maximum reward in healthcare lies in diagnostics, says Incred PMS' Aditya Khemka
For investors in hospital stocks, Khemka says the right time for entry is when the company has completed its capex, because the downside potential from that level is less, while the upside is good.
